Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management

Stock Information for Medicenna Therapeutics Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medicenna Therapeutics Corp.

Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
Canadian Investment Regulatory Organization Trade Resumption - MDNA
Canadian Investment Regulatory Organization Trading Halt - MDNA
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.